Calcitonin in the prevention and therapy of osteoporotic syndromes.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
L V Avioli

Abstract

It is now generally accepted that estrogen status, exercise and adequate calcium intake are the singularly most important factors which guarantee the assumption of genetically programmed peak bone mass. Physicians also recognize that estrogen replacement therapy is not only essential to prevent bone loss in the early postmenopausal female, but also for the long-term preservation of bone mineral density. The efficacy of either continuous or intermittent calmon calcitonin administration in preventing further bone loss and in some instances decreasing fracture incidences in established osteoporotic syndromes is currently well established. As noted during a variety of controlled investigations performed both in the United States and abroad, and in the Physician's Resource Manual on Osteoporosis published by the United States National Osteoporosis Foundation, salmon calcitonin is also effective in early postmenopausal women who are not candidates for estrogen replacement therapy in addition to those patients with established osteoporosis. The practicing physician should acknowledge that of all the anti-resorptive agents recommended for therapy in osteoporotic syndromes, estrogens and salmon calcitonin are currently the only two drug...Continue Reading

References

Jul 3, 1979·Calcified Tissue International·A ChantraineP Franchimont
Nov 1, 1977·The Journal of Clinical Investigation·H Heath, G W Sizemore
Nov 7, 1992·BMJ : British Medical Journal·J A KanisL Miravet
Apr 1, 1992·Calcified Tissue International·C GennariR Civitelli
Feb 1, 1991·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·R MuffJ A Fischer
Aug 1, 1991·Calcified Tissue International·L MontemurroG Rizzato
Jan 11, 1991·Calcified Tissue International·J H Carstens, J D Feinblatt
Oct 1, 1990·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·M E ArlotP J Meunier
Oct 1, 1990·Calcified Tissue International·G F MazzuoliS Dell'Acqua
Mar 1, 1990·The Journal of Clinical Endocrinology and Metabolism·R PacificiL V Avioli
Aug 19, 1989·BMJ : British Medical Journal·K OvergaardM A Hansen
Apr 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·R PacificiW A Peck
Oct 1, 1989·American Journal of Obstetrics and Gynecology·R B MazessW Utian
Apr 23, 1988·Lancet·I MacIntyreM J Healy
Sep 15, 1988·The New England Journal of Medicine·UNKNOWN Ludwig Breast Cancer Study Group
Mar 1, 1985·Annals of Internal Medicine·B EttingerC E Cann
Jun 1, 1986·American Journal of Obstetrics and Gynecology·K A SteingoldR J Chang
Jun 1, 1986·Calcified Tissue International·A ChantraineC M Lapiere
Oct 1, 1987·The Journal of Clinical Endocrinology and Metabolism·K SteingoldR J Chang
Oct 1, 1988·The Journal of Clinical Investigation·R CivitelliC Gennari
Jan 1, 1987·European Journal of Clinical Pharmacology·J D Ringe, D Welzel
Jul 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·R PacificiW A Peck
Dec 1, 1987·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·J PødenphantC Christiansen
Dec 1, 1985·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·J ZséliI Holló
Dec 1, 1970·Metabolism: Clinical and Experimental·C L DonaldsonD E McMillan
Jan 1, 1974·Calcified Tissue Research·P MinaireJ Bourret
Nov 29, 1973·The New England Journal of Medicine·G L WarneF I Martin
Nov 1, 1983·The Journal of Clinical Endocrinology and Metabolism·J J Body, H Heath
Dec 1, 1983·The American Journal of Medicine·B L Riggs, L J Melton
Jan 1, 1982·Cancer Chemotherapy and Pharmacology·A C HindleyA E Wiles
Aug 4, 1983·The New England Journal of Medicine·A D Adinoff, J R Hollister

❮ Previous
Next ❯

Citations

Apr 17, 2010·Bulletin of Experimental Biology and Medicine·L K PeshekhonovaD V Peshekhonov

❮ Previous
Next ❯

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.